

Specific Technologies Announces that Allan Harris Joins its Advisory Board effective March 31, 2016

MOUNTAIN VIEW, California, March 15, 2016 -- Specific Technologies, which has developed a new paradigm combining detection with ID of microorganisms growing in culture, is very pleased to announce that Mr. Allan Harris, Vice President Corporate Strategy at Hologic, has joined Specific's Advisory Board effective March 31, 2016. Mr. Harris brings 25 years of active industry experience in corporate strategy, marketing and investor relations. Prior to joining Hologic in a senior position responsible for diagnostics strategy development and merger/acquisition activities, Allan rose through a number of positions at Beckman Coulter, both before and after its acquisition by Danaher. Most recently, as Beckman's Senior Vice President of Corporate Strategy Allan led Beckman's successful acquisition of Siemens Microbiology and its Microscan business, the world's number two platform for automated susceptibility testing.

"Allan's deep understanding of the hospital laboratory space and diagnostic instruments broadly will be of great value to Specific as we launch our first commercial product, the Spec80 benchtop system, which will revolutionize blood culture by combining detection with Gram status determination and ID," said Paul A. Rhodes, Specific Technologies' CEO. "His deep appreciation for the current commercial landscape and future trajectory in automated susceptibility testing will be invaluable as we engineer and deliver a whole product line of transformative products, in blood culture detection and ID and far beyond. He adds a seasoned appreciation of the realities of corporate competition in the diagnostic space at a time when we are entering that arena."

Allan Harris stated, "I am very pleased to join the Advisory Board of this innovative company, which is bringing a novel paradigm to combine detection and ID during the growth of microorganisms in culture. By combining previously separate often labor intensive or costly steps into one entirely hands free low cost step, Specific is providing clinical microbiology exactly the type of solution that is needed, at exactly the time when the combined cost and performance pressures in microbiology diagnostics require it. Furthermore, the streamlined workflow inherently streamlines information flow, with detection and ID results all emerging in realtime, 24/7, into lab information systems regardless of floor staffing. I am pleased that my experience can contribute to helping Specific address these opportunities."

About the SpecID System

During growth in culture, bacteria produce small molecule volatile metabolites unique to their species and strain. Utilizing an inexpensive printed chemical sensor array to obtain a fingerprint that combines detection and identification into a simple, automated single step, the novel SpecID system identifies microorganism species and strain from a phenotypic metabolomic signature obtained during growth. The fully automated system will streamline lab work flow, reduce costs, and substantially shorten the time from sample arrival to the Gram status and species ID determination, truly lowering costs while improving patient care by speeding sample-to-answer in blood culture and soon other clinically important samples.

About Specific Technologies

Specific Technologies has developed *in vitro* diagnostic systems for rapid identification of cells at the strain level, and is applying this fundamental new platform to the detection and characterization of microorganisms during culture. The company's unique, patented metabolomic signature technology leverages a low-cost printed chemical colorimetric sensor array to identify cell type down to the strain level. Specific Technologies is located in Mountain View, CA.

Press Release – For Distribution

For additional information, please visit www.specifictechnologies.net.

Corporate Contact:

Email: press@specifictechnologies.net